Search details
1.
K128 ubiquitination constrains RAS activity by expanding its binding interface with GAP proteins.
EMBO J
; 2024 Jun 10.
Article
in English
| MEDLINE | ID: mdl-38858602
2.
Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy.
Br J Haematol
; 204(4): 1439-1449, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-37807708
3.
Length-Dependent Translation Efficiency of ER-Destined Proteins.
Curr Issues Mol Biol
; 45(8): 6717-6727, 2023 Aug 14.
Article
in English
| MEDLINE | ID: mdl-37623244
4.
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
J Transl Med
; 21(1): 197, 2023 03 15.
Article
in English
| MEDLINE | ID: mdl-36922828
5.
Assembly and specific recognition of k29- and k33-linked polyubiquitin.
Mol Cell
; 58(1): 95-109, 2015 Apr 02.
Article
in English
| MEDLINE | ID: mdl-25752577
6.
Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.
Int J Mol Sci
; 24(6)2023 Mar 15.
Article
in English
| MEDLINE | ID: mdl-36982699
7.
Mechanism of phospho-ubiquitin-induced PARKIN activation.
Nature
; 524(7565): 370-4, 2015 Aug 20.
Article
in English
| MEDLINE | ID: mdl-26161729
8.
Active site alanine mutations convert deubiquitinases into high-affinity ubiquitin-binding proteins.
EMBO Rep
; 19(10)2018 10.
Article
in English
| MEDLINE | ID: mdl-30150323
9.
Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis.
Haematologica
; 106(2): 601-604, 2021 02 01.
Article
in English
| MEDLINE | ID: mdl-32381580
10.
Erratum: Mechanism of phospho-ubiquitin-induced PARKIN activation.
Nature
; 526(7575): 728, 2015 Oct 29.
Article
in English
| MEDLINE | ID: mdl-26416742
11.
Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.
Hematol Oncol
; 38(3): 412-414, 2020 Aug.
Article
in English
| MEDLINE | ID: mdl-32323881
12.
Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
Am J Hematol
; 94(1): E35-E37, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30370955
13.
Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma.
Clin Cancer Res
; 29(1): 279-288, 2023 01 04.
Article
in English
| MEDLINE | ID: mdl-36282272
14.
Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma.
Cancers (Basel)
; 15(2)2023 Jan 15.
Article
in English
| MEDLINE | ID: mdl-36672481
15.
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.
J Clin Oncol
; 41(7): 1383-1392, 2023 03 01.
Article
in English
| MEDLINE | ID: mdl-36315921
16.
Deubiquitinase OTUD1 Resolves Stalled Translation on polyA and Rare Codon Rich mRNAs.
Mol Cell Biol
; 42(12): e0026522, 2022 12 15.
Article
in English
| MEDLINE | ID: mdl-36445135
17.
The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma.
Nat Commun
; 13(1): 6820, 2022 11 10.
Article
in English
| MEDLINE | ID: mdl-36357400
18.
The transmembrane adaptor protein NTAL signals to mast cell cytoskeleton via the small GTPase Rho.
Eur J Immunol
; 40(11): 3235-45, 2010 Nov.
Article
in English
| MEDLINE | ID: mdl-21061444
19.
Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment.
Cells
; 10(5)2021 04 21.
Article
in English
| MEDLINE | ID: mdl-33919155
20.
A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers.
Cancers (Basel)
; 12(5)2020 May 23.
Article
in English
| MEDLINE | ID: mdl-32456165